Download PDF
Dtsch Med Wochenschr 2013; 138(50): 2599-2612
DOI: 10.1055/s-0033-1349567
CME | Review article
Hepatologie, Immunologie
© Georg Thieme Verlag KG Stuttgart · New York

Autoimmunhepatitis

Autoimmune hepatitis
C. Jüngst
1   Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes
,
F. Lammert
1   Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes
,
C. P. Strassburg
2   Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn
› Author Affiliations
Further Information

Publication History

13 May 2013

27 August 2013

Publication Date:
03 December 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Autoimmunhepatitis - Autoantikörper - Azathioprin - Budesonid - Immunsuppressive Therapie - Lebertransplantation

Keywords

autoimmune hepatitis - autoantibodies - azathioprin - budesonide - immunosuppressive therapy - liver transplantation
 

  • Literatur

  • 1 Al-Chalabi T, Boccato S, Portmann BC et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-583
    CrossrefPubMedGoogle Scholar
  • 2 Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
    CrossrefPubMedGoogle Scholar
  • 3 Bjornsson E, Talwalkar J, Treeprasertsuk S et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-2048
    CrossrefPubMedGoogle Scholar
  • 4 Boberg KM, Chapman RW, Hirschfield GM et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385
    CrossrefPubMedGoogle Scholar
  • 5 Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-497
    CrossrefPubMedGoogle Scholar
  • 6 Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007; 1: 113-128
    CrossrefPubMedGoogle Scholar
  • 7 Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010; 55: 2144-2161
    CrossrefPubMedGoogle Scholar
  • 8 Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72 e54
    CrossrefPubMedGoogle Scholar
  • 9 Feld JJ, Dinh H, Arenovich T et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62
    CrossrefPubMedGoogle Scholar
  • 10 Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-1629
    CrossrefPubMedGoogle Scholar
  • 11 Gonzalez-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001; 7: 302-310
    CrossrefPubMedGoogle Scholar
  • 12 Gregorio GV, Portmann B, Reid F et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547
    CrossrefPubMedGoogle Scholar
  • 13 Hempfling W, Grunhage F, Dilger K et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202
    PubMedGoogle Scholar
  • 14 Hennes EM, Oo YH, Schramm C et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am J Gastroenterol 2008; 103: 3063-3070
    CrossrefPubMedGoogle Scholar
  • 15 Hennes EM, Zeniya M, Czaja AJ et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
    CrossrefPubMedGoogle Scholar
  • 16 Ichai P, Duclos-Vallee JC, Guettier C et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003
    CrossrefPubMedGoogle Scholar
  • 17 Ilyas JA, O'Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011; 25: 765-782
    CrossrefPubMedGoogle Scholar
  • 18 Kanzler S, Gerken G, Lohr H et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34: 354-355
    CrossrefPubMedGoogle Scholar
  • 19 Kanzler S, Lohr H, Gerken G et al. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001; 39: 339-341, 344-348
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011; 55: 171-182
    CrossrefPubMedGoogle Scholar
  • 21 Manns MP, Czaja AJ, Gorham JD et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213
    CrossrefPubMedGoogle Scholar
  • 22 Manns MP, Woynarowski M, Kreisel W et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
    CrossrefPubMedGoogle Scholar
  • 23 Mederacke I, Helfritz F, Puls F et al. Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann Hepatol 2012; 11: 143-144
    PubMedGoogle Scholar
  • 24 Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol 2008; 14: 3360-3367
    CrossrefPubMedGoogle Scholar
  • 25 Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-1145
    CrossrefPubMedGoogle Scholar
  • 26 Potthoff A, Deterding K, Trautwein C et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol 2007; 45: 15-19
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857
    CrossrefPubMedGoogle Scholar
  • 28 Schramm C, Herkel J, Beuers U et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101: 556-560
    CrossrefPubMedGoogle Scholar
  • 29 Sockalingam S, Blank D, Abdelhamid N et al. Identifying opportunities to improve management of autoimmune hepatitis: Evaluation of drug adherence and psychosocial factors. J Hepatol 2012; 57: 1299-1304
    CrossrefPubMedGoogle Scholar
  • 30 Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002; 22: 339-352
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Strassburg CP, Manns MP. Autoimmune hepatitis in the elderly: what is the difference?. J Hepatol 2006; 45: 480-482
    CrossrefPubMedGoogle Scholar
  • 32 Strassburg CP, Manns MP. Therapy of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 673-687
    CrossrefPubMedGoogle Scholar
  • 33 Strassburg CP. Autoimmune hepatitis: new guidelines, new therapies. Dig Dis 2012; 30 Suppl 1: 11-19
    CrossrefPubMedGoogle Scholar
  • 34 van Gerven NM, Verwer BJ, Witte BI et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-147
    CrossrefPubMedGoogle Scholar
  • 35 Vergani D, Longhi MS, Bogdanos DP et al. Autoimmune hepatitis. Semin Immunopathol 2009; 31: 421-435
    CrossrefPubMedGoogle Scholar
  • 36 Vogel A, Heinrich E, Bahr MJ et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18: 62-69
    CrossrefPubMedGoogle Scholar
  • 37 Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 2011; 55: 747-749
    CrossrefPubMedGoogle Scholar
  • 38 Weiler-Normann C, Lohse AW. Treatment adherence – Room for improvement, not only in autoimmune hepatitis. J Hepatol 2012; 57: 1168-1170
    CrossrefPubMedGoogle Scholar